MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12885-026-15829-2

Медицинская библиотека · BMC cancer · 2026

Nivolumab for unresectable cutaneous epithelial malignancies: an open-label, single-arm, multi-centre, phase II trial (NMSC-PD1).

Nakamura Yoshio, Yamazaki Naoya, Namikawa Kenjiro, Uchi Hiroshi, Mori Shoichiro, Ogawa-Momohara Mariko, Fujimura Taku, Takenouchi Tatsuya, Kurimoto Mana, Yamamoto Yuki, Otsuka Atsushi, Kabashima Kenji, Fusumae Takayuki, Hirai Ikuko, Tanese Keiji, Saito Yasuko, Amagai Masayuki, Takemura Ryo, Sato Yasunori, Funakoshi Takeru

СтатьяКлиническое исследование II фазыМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Data in East Asian patients and in other epithelial skin cancers, including extramammary Paget's disease (EMPD) and adnexal carcinomas, are scarce. Therefore, we conducted a phase II trial of nivolumab in Japanese patients with advanced non-melanoma skin cancers (NMSCs).

PATIENTS AND

METHODS

This multicentre, open-label, single-arm phase II study enrolled adults (≥ 20 years) with histologically confirmed unresectable or recurrent epithelial cutaneous malignancies, Eastern Cooperative Oncology Group performance status 0-1, and at least one measurable lesion (RECIST v1.1). Nivolumab 480 mg was administered intravenously every 4 weeks for up to 26 cycles. The primary endpoint was overall response rate (ORR), assessed by blinded independent central review (BICR; RECIST v1.1). Secondary endpoints included progression-free survival, overall survival, and safety.

RESULTS

Thirty-one patients were enrolled (20 cSCC, 4 EMPD, 2 BCC, 5 other NMSCs); median age was 73 years (range 58-86), and 71% were male. ORR by BICR was 22.6% (7/31), and the disease control rate was 54.8% (17/31). Responses were durable, with a median duration of 21.3 months. In the cSCC cohort, median tumour mutational burden (TMB) was 9.0 mut/Mb, lower than in Western series; among three patients with TMB ≥ 30 mut/Mb, two achieved objective responses. Common adverse events included pyrexia, hypothyroidism, adrenal insufficiency, and pruritus.

CONCLUSIONS

Nivolumab showed durable antitumour activity with manageable toxicity in Japanese patients with advanced NMSCs, including rare non-cSCC. The lower ORR compared with Western trials may reflect intrinsic biological differences and support biomarker-driven, region-specific immunotherapy.

CLINICAL TRIAL REGISTRATION: jRCT2031190048; registered 2 July 2019.

Для цитирования: Nakamura Yoshio, Yamazaki Naoya, Namikawa Kenjiro, Uchi Hiroshi, Mori Shoichiro, Ogawa-Momohara Mariko, Fujimura Taku, Takenouchi Tatsuya, Kurimoto Mana, Yamamoto Yuki, Otsuka Atsushi, Kabashima Kenji, Fusumae Takayuki, Hirai Ikuko, Tanese Keiji, Saito Yasuko, Amagai Masayuki, Takemura Ryo, Sato Yasunori, Funakoshi Takeru. Nivolumab for unresectable cutaneous epithelial malignancies: an open-label, single-arm, multi-centre, phase II trial (NMSC-PD1).. BMC cancer. 2026. DOI: 10.1186/s12885-026-15829-2.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.